Alembic Ltd.
Snapshot View

117.70 -3.50 ▼-2.9%

05 August 2021, 04:00:00 P.M.
Volume: 71,522

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.alembiclimited.com
Financial Indicators
Market Cap 3,022.32 Cr.
Earnings per share (EPS) 13.35 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 8.82 Trailing Twelve Months Ending 2021-03
Industry PE 32.75 Trailing Twelve Months Ending 2021-03
Book Value / Share 89.45 Trailing Twelve Months Ending 2021-03
Price to Book Value 1.32 Calculated using Price: 117.70
Dividend Yield 0.17 Period Ending 2021-03
No. of Shares Subscribed 25.68 Cr. 256,781,828 Shares
FaceValue 2
Company Profile

Alembic was incorporated in 1907 as Alembic Chemical Works Company, primarily engaged in production of tinctures and alcohol at Baroda. Later the company set up distillery plant for pharmaceutical purposes at Baroda. It started manufacturing of cough syrup, vitamins, tonics and sulphur drugs.

In 1952, the company set up its research and development activity. Currently the company has developed research activity in area of chemistry, microbiology, pharmaceutical technology and bio-equivalence.

The company’s manufacturing units are located in Baroda and Baddi. Company’s plant has received various certifications such as ISO-9002, ISO-14001 and ISO 27001 and also follows WHO-GMP guidelines.

The company has presence in 75 countries globally.

Business area

APIs- The Company is engaged in manufacturing of active pharmaceutical ingredients for anti-parkinsons, anti-depressants, cephalosporins, macrolides and others.

Bulk Pharmaceuticals- Under this the company manufactures bulk drugs that are phosgene based and intermediates.

Formulation- The company manufactures around 150 products under this segment in therapeutic areas such as anti-infective, cough and cold products to cardiovascular and oral anti-diabetics.

Herbal and Nutraceuticals- The company manufactures herbal and Nutraceuticals and has created brands like Isovon, Protinules, ALA-100, Diax and many more.

Alembic also provides contract research services in area of chemistry, bioequivalence and bioanalytical. It also manufactures products for animal care such as Antibiotics-injections, Analgesics, Antipyretics, antidiarrhoeals, Vitamins-Oral and injectable, Tonics and Nutritional feed supplements.

Outlook

The company has acquired API manufacturing unit of Nirayu that is located at Gujarat at a consideration of Rs 17.50 Crores.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
-2.89%
1 Week
-4.07%
1 Month
-8.12%
3 Month
-9.53%
6 Month
+19.01%
1 Year
+32.77%
2 Year
+176.94%
5 Year
+209.74%
9 years 2009-03 2010-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03
Return on Equity (%) 3.22 11.83 5.58 3.71 3.21 4.18 3.58 7.08 0.75
Return on Capital Employed (%) 7.79 10.54 3.82 3.82 3.12 4.44 3.91 7.12 0.94
Return on Assets (%) 1.08 3.82 2.88 3.25 2.94 3.88 3.39 6.80 0.71

Balance Sheet View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Shh. Funds 528 803 911 1,086 1,209 1,418 2,297
Non Curr. Liab. 38 15 13 14 9 7 53
Curr. Liab. 82 58 68 59 49 46 59
Minority Int.
Equity & Liab. 648 876 992 1,159 1,266 1,471 2,409
Non Curr. Assets 458 706 801 972 1,167 1,308 2,307
Curr. Assets 189 169 191 187 99 163 102
Misc. Exp. not W/O
Total Assets 648 876 992 1,159 1,266 1,471 2,409

Profit Loss View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Net Sales 144 128 147 125 124 74 74
Other Income 22 29 31 37 29 94 11
Total Income 166 156 178 162 153 167 84
Total Expenditure -135 -122 -140 -114 -106 -71 -63
PBIDT 30 35 38 48 48 97 21
Interest -1 0 0 0 0 0 0
Depreciation -6 -6 -5 -4 -3 -3 -4
Taxation 1 -1 1 -2 -4 0 -3
Exceptional Items -3 -6
PAT 24 25 27 42 41 93 14

Cash Flow View Details

Particulars 7 years 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr.
Cash Fr. Operatn. 22 10 52 24 22 7 -2
Cash Fr. Inv. 5 -5 -47 -22 72 57 -35
Cash Fr. Finan. -25 -5 -5 -3 -92 -6 -15
Net Change 2 0 0 -1 1 57 -52
Cash & Cash Eqvt 3 2 2 1 2 59 7

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 65.22 66.31 67.09 67.62 69.57 70.41 70.41 70.88 70.88
Public 34.78 33.69 32.91 32.38 30.43 29.59 29.59 29.12 29.12
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Tue, 03 Aug 2021
Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) has requested the Company for issue of duplicate share certificate(s):

Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company.

We request you to kindly take the same on record.
Wed, 28 Jul 2021
Board Meeting Intimation for Board Meeting To Consider Unaudited Financial Results For The Quarter Ended 30Th June 2021
ALEMBIC LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2021 inter alia to consider and approve With reference to the captioned matter the Exchange is hereby informed that a Meeting of Board of Directors of the Company will be held on Friday 6th August 2021 inter alia to consider and approve Unaudited Financial Results of the Company for the quarter ended 30th June 2021.

Pursuant to the Companys Code of Conduct for Regulating Monitoring and Reporting of Trading by Designated Persons and their Immediate Relatives the trading window for dealing in securities of the Company which was closed from 1st July 2021 will reopen 48 hours after the declaration of the financial results.

We request you to kindly take the same on record.
Mon, 19 Jul 2021
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform the exchange that the following share certificate(s) of the Company has been reported as lost/misplaced and the shareholder of such lost share certificate(s) have requested the Company for issue of duplicate share certificate(s):

Also find attached herewith copy of email received from RTA as a proof of date of receipt of information by the Company.

We request you to kindly take the same on record.

Technical Scans View Details

Thu, 05 Aug 2021
Higher Delivery Quantity Higher Delivery Quantity
Close Crossing Last Week Low Close Crossing Last Week Low
Close Crossing Last Month Low Close Crossing Last Month Low
Close Crossing Last Month Close from Above Close Crossing Last Month Close from Above
Opening at High Opening at High

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 188,551.74 785.85 +0.0%
Divi's Laboratories Ltd. 130,702.13 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. 79,575.04 4,783.30 +0.2%
Cipla Ltd. 76,243.85 945.20 +0.6%
Cadila Healthcare Ltd. 59,868.47 584.80 -0.5%
Piramal Enterprises Ltd. 59,065.41 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. 58,599.44 4,075.50 +0.2%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 31.41 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 65.87 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.80 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 31.70 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 28.06 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 44.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 389.73 4,075.50 +0.2%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-06 3.94 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 14.06 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.45 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 4.17 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 4.61 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.73 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.75 4,075.50 +0.2%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 0.00 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 0.10 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1.16 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 23.90 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 14.13 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 3.33 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,075.50 +0.2%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 32.07 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 17.85 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 10.03 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,075.50 +0.2%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 6,969.40 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 19,159.59 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 12,809.35 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,075.50 +0.2%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 785.85 +0.0%
Divi's Laboratories Ltd. Consolidated 2021-03 1,984.29 4,923.45 -0.9%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,783.30 +0.2%
Cipla Ltd. Consolidated 2021-03 2,401.30 945.20 +0.6%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 584.80 -0.5%
Piramal Enterprises Ltd. Consolidated 2021-03 1,074.43 2,601.15 +2.0%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,075.50 +0.2%